相关实验视频

Updated: Jun 29, 2025

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases

Published on: October 10, 2020

在体外低剂量的博特佐米布会诱导亡并独立降低多发性骨髓瘤中氨酸S转移酶和氨酸过氧化酶的活性,考虑到GSTT1和GSTM1基因变异

Szymon Zmorzynski¹, Sylwia Popek-Marciniec¹, Beata Biernacka²

¹Laboratory of Genetics, Academy of Zamosc, 22-400 Zamosc, Poland.

|March 28, 2024

概括

在多发性骨髓瘤细胞中,博特佐米布治疗会改变谷氨酶活性,在某些药物度下,特定的基因变异 (GSTT1,GSTM1) 会影响这些变化.

科学领域:

在瘤学瘤学.
药物基因组学药物基因组学
生物化学生物化学

背景情况:

多发性骨髓瘤 (MM) 是血细胞的癌症.
博尔特佐米布是MM的关键治疗剂.
谷氨 (GSH) 及其相关酶在细胞保护和药物代谢中发挥作用.

研究的目的:

研究博特佐米布对MM细胞中谷氨水平和酶活性的影响.
分析GSTT1和GSTM1基因变异与这些生化变化之间的关联.

主要方法:

在MM患者和健康捐赠者中使用多重PCR对GSTT1和GSTM1基因进行基因定型.
在体外治疗MM骨髓细胞,使用不同度的博特佐米布 (1-4nM).
通过光显微镜和ELISA评估亡,GSH度和谷氨酶活性 (GST,GPx).

主要成果:

博尔特佐米布诱导了亡,并降低了GST和谷氨过氧化酶 (GPx) 的活性.
在GSTT1-null和GSTT1-present基因型之间观察到GSTT1活动的显著差异,在1和2nM bortezomib.
在GSTM1-null和GSTM1-present基因型之间,GST活性在4nM的博特佐米布之间也存在差异.

结论:

博尔特佐米布会影响GST和GPx酶的活性.
GST活动与GSTT1和GSTM1基因变异有关,特别是在特定的博特佐米布度下.

关键词:

灭症 (apoptosis) 是一种死亡的过程.博尔特佐米布 (Bortezomib) 是一种药物.谷氨酸S转移酶是一种S转移酶.谷氨过氧化酶是什么?谷氨减少酶可以减少谷氨.多发性骨髓瘤是多发性骨髓瘤的一种疾病.减少的谷氨二甲可以减少.

更多相关视频

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

The Intrinsic Apoptotic Pathway

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...

In-vitro Mutagenesis

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.